drugset / Trial / NCT07340489
Serplulimab for Locally Advanced Cervical Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, controlled, open-label, phase II clinical trial designed to enroll patients with previously untreated locally advanced cervical cancer. The study aims to evaluate the efficacy and safety of adding chemotherapy to serplulimab combined with concurrent chemoradiotherapy. The primary endpoint of this study is progression-free survival (PFS).
Timeline
- Start
- 2025-12-03
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |